Entries by Mark Gowland

Fennec Provides Corporate Update and Announces Third Quarter 2015 Financial Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Nov. 12, 2015) – Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the third quarter ended September 30, 2015. “We continue to make progress in the development […]

FENNEC TO PRESENT AT RODMAN & RENSHAW 17TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK ON SEPTEMBER 10, 2015

Research Triangle Park, NC, September 3, 2015 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City at 5:05 EDT on Thursday, September 10, 2015. The conference is being held at the St. […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Aug. 11, 2015) – Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the second quarter ended June 30, 2015. “The second quarter was instrumental in the […]

Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – May 31, 2015) – Fennec Pharmaceuticals, Inc. (TSX:FRX) (OTCQB:FENCF), announced the presentation of positive interim results from a poster presented today entitled, “Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) […]

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – May 28, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the “Circular”) for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held […]

FENNEC PROVIDES CORPORATE UPDATE AND FIRST QUARTER ENDED MARCH 31, 2015 FINANCIAL RESULTS

SIOPEL 6 Safety Data Featured in Poster at ASCO 2015 Strengthening of financial position through warrant proceeds Presenting at Jefferies 2015 Global Healthcare Conference  Research Triangle Park, NC, May 15, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of […]

FENNEC ANNOUNCES AVAILABILITY OF SIOPEL 6 STUDY ABSTRACT FOR ASCO 2015 MEETING

End of treatment anti-tumor efficacy in Standard Risk Hepatoblastoma patients shows no adverse outcome related to Sodium Thiosulfate Research Triangle Park, NC, May 14, 2015 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled  “Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised […]

FENNEC PHARMACEUTICALS ANNOUNCES THE EXERCISE OF WARRANTS BY THE COMPANY’S LARGEST SHAREHOLDER AND PROVIDES UPDATED CORPORATE CAPITAL STRUCTURE

Fennec receives net proceeds of $0.45 million from the exercise of warrants Research Triangle Park, NC, May 4, 2015 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today reported that Southpoint Master Fund, LP (“Southpoint”), the Company’s largest shareholder with 36.6% of Fennec’s issued and outstanding shares has exercised 0.3 million warrants at a price […]

FENNEC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND FISCAL YEAR ENDED DECEMBER 31, 2014 FINANCIAL RESULTS

SIOPEL 6 SAFETY DATA UPDATE SUBMITTED TO ASCO 2015 RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – April 1, 2015) – Fennec Pharmaceuticals Inc. (FRX.TO)(FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the […]

FENNEC PHARMACEUTICALS ANNOUNCES THAT THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) RECOMMENDS THE CONTINUATION OF SIOPEL 6 PHASE 3 CLINICAL TRIAL

Positive recommendation after final safety review of 100 Patients Research Triangle Park, NC, February 2, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical […]

FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN SODIUM THIOSULFATE PHASE 3 SIOPEL 6 STUDY

116 total patients enrolled Independent safety data review of first 100 patients expected Q1 2015 Research Triangle Park, NC, January 5, 2015 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is […]

FENNEC ANNOUNCES PRIVATE PLACEMENT OF UNITS

Research Triangle Park, NC, December 3, 2014 – – Fennec Pharmaceuticals Inc. (the “Company” or “Fennec”) (TSX: FRX, OTCQB: FENCF), announced today that it has completed a non-brokered private placement (the “Offering”) of 732,266 units for gross proceeds of US$2,196,798. Each unit (a “Unit”) was issued at a price of US$3.00 per Unit and consists […]

FENNEC PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND THIRD QUARTER ENDED SEPTEMBER 30, 2014 FINANCIAL RESULTS

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Nov. 13, 2014) – • SIOPEL 6 Has Enrolled 112 Patients With Study Completion Expected by Year End • Safety Data on 100 Patients Expected During Q1 2015 • Name Change, Warrant Exchange and Share Consolidation Completed Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today reported its financial results and recent developments […]

FENNEC PHARMACEUTICALS ANNOUNCES OVER THE COUNTER TRADING SYMBOL CHANGE

RESEARCH TRIANGLE PARK, NC, Sept. 5, 2014 – Fennec Pharmaceuticals Inc. (TSX: FRX; OTC: ADHXD) (the “Company”) formerly known as Adherex Technologies Inc., today announced that the Financial Industry Regulatory Authority (“FINRA”) has approved the Company’s corporate actions regarding its previously announced name change and share consolidation. As of open of business on September 5, […]

ADHEREX ANNOUNCES SHARE CONSOLIDATION, NAME CHANGE AND TRADING SYMBOL CHANGE

RESEARCH TRIANGLE PARK, NC, Sept. 3, 2014 – Adherex Technologies Inc. (TSX: AHX; OTC: ADHXF) (the “Company”) announced today that it gave effect to the consolidation of its outstanding share capital on the basis of one new security for every three outstanding securities (the “Consolidation”).  In addition, the Company filed a Notice of Alteration with […]

ADHEREX ANNOUNCES WARRANT EXCHANGE RESULTS AND NEW CAPITAL STRUCTURE

Research Triangle Park, NC, August 8, 2014 – – Adherex Technologies Inc. (TSX: AXH, OTCQB: ADHXF), today reported the final results of the Warrant exchange which concluded on July 29, 2014.  Approximately, 71% of all outstanding warrants originally issued by the Company on April 30, 2010 and 48% of all outstanding warrants issued on March 29, 2011 participated in the exchange. […]

ADHEREX TECHNOLOGIES INC. ANNOUNCES WARRANT EXCHANGE

RESEARCH TRIANGLE PARK, NC, June 30, 2014 – Adherex Technologies Inc. (TSX: AHX; OTC: ADHXF) (the “Company”) today announced it is offering holders of warrants originally issued by the Company on or about April 30, 2010 and March 29, 2011 the opportunity to exchange 180 warrants for one new warrant to purchase one share of […]

ADHEREX ANNOUNCES RESULTS FROM TWO SODIUM THIOSULFATE PHASE 3 STUDIES PRESENTED AT THE 50TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING

  –COG STUDY ACCL0431 meets primary endpoint for prevention of cisplatin-induced hearing loss in children -SIOPEL 6 Data Monitoring Committee recommends continuation of study after safety review of 80 standard risk hepatoblastoma patients   Research Triangle Park, NC — June 2, 2014 – Adherex Technologies, Inc. (TSX: AHX, OTC: ADHXF) today announced the results on the […]